Pneumothorax during Alectinib Treatment for a Uterine Inflammatory Myofibroblastic Tumor with Lung Metastasis by Chang-Ting Lin, Chen-Hsuan Wu, Hsuan-Ying Huang, Chien-Ting Liu

Subjects: “…alectinib…”
Get full text

Safety of brigatinib following alectinib-induced-pneumonitis: Case report by Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman

Subjects: “…Alectinib…”
Get full text

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic revi... by Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Subjects: Get full text

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report... by Kei Kunimasa, Akito Miyazaki, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Tsunehiro Tanaka, Shun Futamura, Kiyohide Komuta, Shigenori Nagata, Keiichiro Honma, Kazuyoshi Ohkawa, Kazumi Nishino

Subjects: Get full text

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review by Hongxia Wang, Junjun Bai, Bei Zhang, Zhixin Pei, Yingxin Zhao, Jingjing Gu, Zhiyu Fang, Miaomiao Liu, Xun Liang, Qinglin Song

Subjects: Get full text

Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System by Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan

Subjects: Get full text

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC by Lianxi Song, MD, Huan Yan, MD, Qinqin Xu, MD, Chunhua Zhou, MD, Juan Liang, MD, Shaoding Lin, MD, Ruiguang Zhang, MD, Juan Yu, MD, Yang Xia, MD, Nong Yang, MD, Liang Zeng, MD, Yongchang Zhang, MD

Subjects: “…Alectinib…”
Get full text

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inh... by Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, William W. L. Wong

Subjects: Get full text

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma by Brenda Paola Rodriguez Arroyo, Alvaro Mondragón-Cardona, Rafael Adrián Pacheco-Orozco, Andrea Tamayo, Juan Camilo Moreno, Juan Camilo Baena-Valencia

Subjects: Get full text

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review by Huang Chen, Menglan Zhang, Liyan Bai, Yun Niu, Xiaowei Wang, Ruiying Jiang, Ye Wang, Qianqian Feng, Bei Wang, Tingli Dai, Mingming Yuan, Rongrong Chen, Yujuan Qi, Dingrong Zhong

Subjects: “…alectinib…”
Get full text